Association between oxybutynin and neuropsychiatric adverse effects not confirmed in daily practice.
Movig
K L
KL
Egberts
A C
AC
Lenderink
A W
AW
Leufkens
H G
HG
D000368:Aged; D000369:Aged, 80 and over; D014150:Antipsychotic Agents / Q000627:therapeutic use; D018680:Cholinergic Antagonists / Q000009:adverse effects*; D011307:Drug Prescriptions / Q000706:statistics & numerical data; D004363:Drug Utilization; D005422:Flavoxate / Q000627:therapeutic use; D006801:Humans; D008333:Mandelic Acids / Q000009:adverse effects*; D001523:Mental Disorders / Q000139:chemically induced*; D008875:Middle Aged; D009422:Nervous System Diseases / Q000139:chemically induced*; D009426:Netherlands; D010276:Parasympatholytics / Q000009:adverse effects*; D010594:Pharmacies; D012189:Retrospective Studies; D012307:Risk Factors; D014555:Urination Disorders / Q000188:drug therapy
D014150:Antipsychotic Agents; D018680:Cholinergic Antagonists; D008333:Mandelic Acids; D010276:Parasympatholytics; D005422:Flavoxate; C005419:oxybutynin